Historical Archive

Generic hospital drugs. Veneto, Piedmont and Abruzzo are the Regions that get the best prices

What comes from the Council of Ministers "is good news, for which we must be grateful above all to the president of Confindustria, Giorgio Squinzi, and to the head of state, Giorgio Napolitano, who have strongly fought in this sense. One 'node' remains to be addressed: the blockage for the whole of 2013 of executive actions against local health authorities and hospitals in the regions under the repayment plan, envisaged by law 189/2012", better known as the 'Balduzzi decree'.

Thus the president of Farmindustria, Massimo Scaccabarozzi, comments on the measures for the acceleration of the payment of the public administration's debts to its suppliers, announced today by the government.

Scaccabarozzi reminds Pharmakronos that "30% of the pharmaceutical industry's turnover is currently blocked due to these credits, which in 60% of cases concern regions in the 'red'. Therefore, if this point is not unlocked", the Government's effort will be thwarted. If all goes well, "and the 4 billion credits are paid, it would really be a foiled danger and a 'breath in the arm' for drug companies, which could, with good liquidity, invest at least in research and development, also creating new jobs.

We must always remember, however, that we are only one item of health care expenditure, which is constantly declining, and that the market is in any case in sharp decline. Furthermore, if the consumption of drugs increases, we are called to pay off the expense. Therefore, it would be important" to intervene structurally on the system, "with a stability pact. And we are always open to dialogue."

From abroad - adds Scaccabarozzi - I have not yet received comments on the measures approved today by the CDM. But in recent days the message that was clearly arriving was that of strong concern. Some companies had already moved to divest from IT

Articoli correlati

Back to top button
Fedaiisf Federazione delle Associazioni Italiane degli Informatori Scientifici del Farmaco e del Parafarmaco